Story perspectives

Eli Lilly to Acquire Ajax for $2.3 B, Adding Blood-Cancer Drug

4/28/2026

Summary

Lilly Acquires Ajax

Eli Lilly announced on April 27 2026 it will acquire Ajax Therapeutics for up to $2.3 billion in cash.
The purchase adds AJ1-11095, a Phase 1 oral JAK2 inhibitor for myelofibrosis and polycythemia vera with a binding mechanism, which analyst Louise Chen said makes the deal strategically sound for broadening Lilly’s oncology portfolio beyond obesity drugs.
Jacob Van Naarden said Lilly will use its blood-cancer expertise to deliver the new drug to patients and hematologists.

Summary

Lilly Expands

The acquisition requires antitrust clearance under the Hart-Scott-Rodino Act.
Lilly and Ajax have hired Ropes & Gray, Cooley and Kirkland & Ellis respectively to handle the transaction’s legal work.
The deal will be recorded under GAAP, affecting Lilly’s results, guidance and earnings reports after closing.
It follows recent CrossBridge Bio and Kelonia Therapeutics purchases, forming a three-deal oncology spree that shows Lilly’s aggressive expansion.

History

Historical Context

Pfizer’s growth has been driven by a string of mega-mergers. After buying Warner-Lambert in February 2000 for $116 billion, it completed the Pharmacia acquisition in April 2003 (?$64 billion), creating the world’s second-largest drugmaker under antitrust review and adding oncology assets like sunitinib. This consolidation pattern set the stage for today’s Lilly-Ajax Therapeutics $2.3 billion blood-cancer deal.

1 of 3

Lilly Acquires Ajax

Eli Lilly announced on April 27 2026 it will acquire Ajax Therapeutics for up to $2.3 billion in cash.
The purchase adds AJ1-11095, a Phase 1 oral JAK2 inhibitor for myelofibrosis and polycythemia vera with a binding mechanism, which analyst Louise Chen said makes the deal strategically sound for broadening Lilly’s oncology portfolio beyond obesity drugs.
Jacob Van Naarden said Lilly will use its blood-cancer expertise to deliver the new drug to patients and hematologists.

1 / 3